Boai NKY Medical Holdings Ltd.

300109

CNE100000SV3

Specialty Chemicals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
20.85 ^CNY	-1.97%		-1.28%	+15.58%

Apr. 26	Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023	CI
Apr. 25	Boai NKY Medical Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Huadao Biopharma Co., Ltd. announced that it has received CNY 20 million in funding from Boai NKY Medical Holdings Ltd., Chongqing Kexing Equity Investment Management Co., Ltd., Sinowisdom Capital and another investor

February 25, 2024

On February 26, 2024, Huadao Biopharma (Shanghai) Co., Ltd. closed the transaction. The transaction inluded participation from returning investors Sinowisdom Capital, Chongqing Kexing Equity Investment Management Co., Ltd. and new investor Yin Ming.

Latest news about Boai NKY Medical Holdings Ltd.

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023	Apr. 26	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Huadao Biopharma Co., Ltd. announced that it has received CNY 20 million in funding from Boai NKY Medical Holdings Ltd., Chongqing Kexing Equity Investment Management Co., Ltd., Sinowisdom Capital and another investor	Feb. 25	CI
Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding	Feb. 18	CI
Huadao Biopharma Co., Ltd. announced that it expects to receive CNY 20 million in funding from Boai NKY Medical Holdings Ltd.	Jan. 09	CI
Beijing Zhongqi Huiyun Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Boai NKY Medical Holdings Ltd.	Jan. 09	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Hangzhou Neoantigen Biotechnology co., LTD. announced that it expects to receive CNY 50 million in funding from Boai NKY Medical Holdings Ltd.	23-08-27	CI
Beijing Liangyuan Biomedical Research Co., Ltd. announced that it expects to receive CNY 50 million in funding from Boai NKY Medical Holdings Ltd.	23-08-27	CI
Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 30, 2023	23-05-24	CI
Boai NKY Medical Holdings Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Boai Nky Medical Holdings Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Boai NKY Medical Holdings Ltd. Announces Executive Appointments	23-03-23	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Boai NKY Medical Sees 64.2% Jump in 2022 Profit	23-01-25	MT
Tranche Update on Boai NKY Medical Holdings Ltd.'s Equity Buyback Plan announced on December 24, 2021.	22-12-21	CI
Boai NKY Medical Holdings Ltd.'s Equity Buyback announced on December 24, 2021 has expired with the repurchase of 21,213,646 shares, representing 6.46% for CNY 402.87 million.	22-12-20	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Tranche Update on Boai NKY Medical Holdings Ltd.'s Equity Buyback Plan announced on December 24, 2021.	22-10-11	CI
Boai NKY Medical Holdings Ltd.(XSEC:300109) added to S&P Global BMI Index	22-09-19	CI
Boai NKY Medical Holdings Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Tranche Update on Boai NKY Medical Holdings Ltd.'s Equity Buyback Plan announced on December 24, 2021.	22-07-03	CI

Chart Boai NKY Medical Holdings Ltd.

Duration

Period

More charts

Company Profile

Boai NKY Medical Holdings Ltd., formerly Boai NKY Pharmaceuticals Ltd., is a China-based company principally engaged in the research, development, production and distribution of polyvinyl pyrrolidone (PVP) series products and polyvinyl methyl ether and maleic anhydride (PVME/MA) series products. The Companyâs main products include GBL, 2- pyrrolidone, N-vinylpyrrolidone (NVP) monomer, PVP-K series (PVPK), polyvinylpolypyrrolidone (PPVP), PVP- Iodine (PVP-I), related pharmaceutical intermediates and others. The Company's products are mainly used in daily chemical, medicine, liquor and beverage, pigments and coatings, textile, paper making, oil extraction, sensitive material, electronic and other industries. The Company distributes its products in domestic market and to overseas markets.

Sector

Specialty Chemicals

Calendar

2024-05-23 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Specialty Chemicals

	1st Jan change	Capi.
BOAI NKY MEDICAL HOLDINGS LTD.	+15.58%	885M
ECOLAB INC.	+11.47%	63.22B
SIKA AG	-2.56%	46.34B
GIVAUDAN SA	+13.69%	39.97B
FUJIFILM HOLDINGS CORPORATION	+17.83%	25.46B
EMS-CHEMIE HOLDING AG	+7.49%	18.68B
CELANESE CORPORATION	-0.57%	17.24B
POSCO FUTURE M CO., LTD.	-21.73%	15.81B
SYMRISE AG	+1.31%	14.9B
ALBEMARLE CORPORATION	-19.10%	13.74B

Other Specialty Chemicals

Boai NKY Medical Holdings Ltd.

Equities

300109

CNE100000SV3

Specialty Chemicals

Huadao Biopharma Co., Ltd. announced that it has received CNY 20 million in funding from Boai NKY Medical Holdings Ltd., Chongqing Kexing Equity Investment Management Co., Ltd., Sinowisdom Capital and another investor

Latest news about Boai NKY Medical Holdings Ltd.

Chart Boai NKY Medical Holdings Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Specialty Chemicals